Drug Trial Radar · NCT04521114
Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Last checked: Nov 19, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
87
Actual
Start
Dec 1, 2020
Primary completion
Dec 29, 2021
Study completion Dec 29, 2021
Sponsor
- Lead sponsor
- CytoDyn, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II study of of Leronlimab (PRO 140)-Humanized monoclonal antibody to CCR5 in patients with Nonalcoholic Steatohepatitis (NASH).
Conditions
- Nonalcoholic Steatohepatitis (NASH)
Interventions
PlaceboDrug
Placebo will be administered subcutaneously every week for 13 weeks.
leronlimab 700 mgDrug
700 mg leronlimab will be administered subcutaneously every week for 13 weeks.
leronlimab 350 mgDrug
350 mg leronlimab will be administered subcutaneously every week for 13 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MRI-PDFF Change From Baseline to Week 14Time frame: Change from baseline (day one, first day of treatment) to EOT (day 92, 13 weeks of treatment)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Southern California Research Center
Coronado, California
Meridien Research
Maitland, Florida
Floridian Clinical Research
Miami Lakes, Florida
Sensible Healthcare, LLC
Ocoee, Florida
Center for Advanced Research & Education
Gainesville, Georgia
Care United Research LLC
Forney, Texas
American Research Corporation
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.